Kenneth J. Pienta

Kenneth J. Pienta

Chief Tech/Sci/R&D Officer presso James Buchanan Brady Urological Institute

64 anni
Consumer Services
Health Technology

Profilo

Kenneth J.
Pienta
is currently the Research Director at James Buchanan Brady Urological Institute and a Professor at The Johns Hopkins University.
He previously held positions as the Director-Prostate Specialized Program at the University of Michigan, Director-Experimental Therapeutics at Michigan Center for Translational Pathology, and Independent Director at Curis, Inc. He was also a Director at GreenMark Biomedical, Inc. and is currently the Chief Medical Officer at Cue Biopharma, Inc. Pienta received his undergraduate degree from The Johns Hopkins University and his doctorate from The Johns Hopkins University School of Medicine.

Posizioni attive di Kenneth J. Pienta

SocietàPosizioneInizio
James Buchanan Brady Urological Institute Chief Tech/Sci/R&D Officer 01/03/2013
The Johns Hopkins University Corporate Officer/Principal 01/01/1994
Tutte le posizioni attive di Kenneth J. Pienta

Precedenti posizioni note di Kenneth J. Pienta

SocietàPosizioneFine
CUE BIOPHARMA, INC. Chief Tech/Sci/R&D Officer 17/01/2023
Director/Board Member 01/01/2020
CURIS, INC. Director/Board Member 01/05/2017
Michigan Center for Translational Pathology Corporate Officer/Principal 01/02/2013
University of Michigan Corporate Officer/Principal -
Vedi nel dettaglio l'esperienza di Kenneth J. Pienta

Formazione di Kenneth J. Pienta

The Johns Hopkins University Undergraduate Degree
The Johns Hopkins University School of Medicine Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Kenneth J. Pienta

Relazioni

100 +

Relazioni di 1° grado

8

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa2
CURIS, INC.

Health Technology

CUE BIOPHARMA, INC.

Health Technology

Aziende private2
Michigan Center for Translational Pathology

Health Technology

Vedi le connessioni aziendali
  1. Borsa valori
  2. Insiders
  3. Kenneth J. Pienta